Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.90 [0.73, 1.10] | | < 1 | | 50% | 3 studies (3/-) | 85.6 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 0.95 [0.78, 1.14] | | < 1 | | 50% | 3 studies (3/-) | 71.7 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.08 [0.86, 1.37] | | > 1 | | 24% | 3 studies (3/-) | 75.5 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.43 [0.15, 1.24] | | < 1 | | 0% | 1 study (1/-) | 94.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.86 [0.56, 1.35] | | < 1 | | 0% | 1 study (1/-) | 74.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 3.45 [1.24, 9.59] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 1.63 [0.91, 2.93] | | < 1 | | 0% | 1 study (1/-) | 5.2 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.93 [1.22, 3.04] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.50 [0.82, 2.75] | | < 1 | | 69% | 2 studies (2/-) | 9.6 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 1.98 [1.32, 2.98] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.34 [0.09, 1.30] | | < 1 | | 93% | 2 studies (2/-) | 94.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.60 [0.23, 1.58] | | < 1 | | 91% | 2 studies (2/-) | 84.9 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.98 [0.31, 3.06] | | < 1 | | 0% | 2 studies (2/-) | 51.3 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 1.85 [0.63, 5.45] | | < 1 | | 86% | 2 studies (2/-) | 13.1 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 5.13 [2.63, 10.00] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Anaemia TRAE (grade 3-4) | 0.11 [0.04, 0.28] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 1.24 [0.33, 4.65] | | < 1 | | 0% | 1 study (1/-) | 37.5 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.99 [0.02, 50.01] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.99 [0.25, 3.99] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 3.00 [0.60, 14.96] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 2.00 [0.60, 6.70] | | < 1 | | 0% | 1 study (1/-) | 13.1 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.28 [0.06, 1.35] | | < 1 | | 0% | 1 study (1/-) | 94.3 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.23] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 3.97 [0.18, 88.42] | | < 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 18.21 [1.05, 315.26] | | < 1 | | 0% | 1 study (1/-) | 2.4 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.10 [0.01, 0.76] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Anaemia AE (grade 3-4) | 1.14 [0.41, 3.20] | | < 1 | | 0% | 1 study (1/-) | 40.0 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 2.01 [0.36, 11.05] | | < 1 | | 0% | 1 study (1/-) | 21.3 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.25 [0.03, 2.22] | | < 1 | | 0% | 1 study (1/-) | 89.3 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.50 [0.04, 5.51] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.00 [0.14, 7.12] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.50 [0.02, 14.89] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 6.03 [0.30, 120.98] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 10.29 [1.31, 80.96] | | < 1 | | 0% | 1 study (1/-) | 1.4 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.87 [0.31, 2.43] | | < 1 | | 0% | 1 study (1/-) | 60.6 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.51 [0.42, 5.39] | | < 1 | | 0% | 1 study (1/-) | 26.5 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 1.00 [0.06, 16.01] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 2.52 [0.48, 13.09] | | < 1 | | 0% | 1 study (1/-) | 13.7 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 2.28 [0.69, 7.50] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 4.01 [0.18, 89.26] | | < 1 | | 0% | 1 study (1/-) | 19.3 % | NA | not evaluable | | non important | - |
Pneumonia AE (grade 3-4) | 1.36 [0.72, 2.56] | | < 1 | | 0% | 1 study (1/-) | 17.2 % | NA | not evaluable | | non important | - |
Pneumonitis AE (grade 3-4) | 2.21 [0.83, 5.91] | | < 1 | | 0% | 1 study (1/-) | 5.6 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.50 [0.04, 5.51] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 6.03 [0.30, 120.98] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 16.38 [0.94, 286.59] | | < 1 | | 0% | 1 study (1/-) | 2.9 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 4.03 [0.45, 36.27] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |